Cargando…
SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies
Individuals with hematological malignancies and hematopoietic stem cell transplant (HCT) recipients are immunologically heterogenous groups with varying degrees of immunosuppression at increased risk of severe disease and mortality from SARS-CoV-2 infection. SARS-CoV-2 vaccines are key interventions...
Autores principales: | Ni, Bin, Yanis, Ahmad, Dee, Kevin, Chappell, James D., Dulek, Daniel E., Kassim, Adetola A., Kitko, Carrie L., Thomas, Lora D., Halasa, Natasha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188822/ https://www.ncbi.nlm.nih.gov/pubmed/35752546 http://dx.doi.org/10.1016/j.blre.2022.100984 |
Ejemplares similares
-
1100. Cellular Immunophenotypic Predictors of Influenza Vaccine Immunogenicity in Pediatric Hematopoietic Cell Transplant Recipients
por: Amarin, Justin Z, et al.
Publicado: (2023) -
HEALTHCARE UTILIZATION IN OLDER ADULTS (≥70 YEARS) UNDERGOING CELLULAR THERAPY FOR HEMATOLOGIC MALIGNANCIES
por: Snider, Christina, et al.
Publicado: (2022) -
568. Comparison of Humoral Immune Response to the SARS-CoV-2 BNT162b2 Vaccine Between Solid Organ Transplant Recipients and Healthy Controls
por: Yanis, Ahmad, et al.
Publicado: (2021) -
2759. Immunogenicity of Inactivated Influenza Vaccines Given Early vs. Late After Pediatric Allogeneic Hematopoietic Cell Transplantation
por: Schuster, Jennifer E, et al.
Publicado: (2019) -
Evaluation of healthcare-associated infection rates in patients with hematologic malignancies and stem cell transplantation during the coronavirus disease 2019 (COVID-19) pandemic
por: Bobbitt, Laura J., et al.
Publicado: (2022)